DIY FLU
agency: Cadient Group
brand: Fluvirin
client: Novartis
photo from left: Sally Reed, manager, project management • Geoff McCleary, senior marketing strategist • Marisa McGettigan, account manager • Erik Sonlin, associate creative director • On Laptop: David Miller, digital media producer
Many pharmaceutical companies are terrified of dipping even a toe into the swirling pool of viewer-generated content because regulatory issues make a truly unfiltered dialogue impossible. However, Cadient made pharma history with its groundbreaking YouTube Fluflix contest for Novartis's influenza vaccine Fluvirin and the firm's informational Web site FluSource.com.
Cadient presented the YouTube concept, and Novartis got on board, offering $500 to anyone who could create a compelling video flu story in one of the following categories: Kids and the Flu, Sports and the Flu, and Workplace and the Flu. The result? At press time, approximately 800,000 people had viewed the sample videos produced by Novartis and Cadient, and approximately 12,000 people had viewed the FluFlix channel on YouTube. The contest—which was unbranded—also drummed up impressive hits for Novartis's FluSource.com. The winning videos included a retro black-and-white entry, a cartoon entry, and a video featuring the filmmaker's own children.
"We met the challenges of the client, and we think we were able to provide the users with a forum to exercise some creativity," says Geoff McCleary of Cadient. "I think the prevailing thought in the pharma industry is that it's a great thing to try social media, we just wish we knew how to do it. This proves that there are ways."
With pharma scaling back, where will this lead? Last time we checked, YouTube videos were cheaper than flashy commercials. And Cadient's Sally Reed was "astounded" by the quality. "The three winners were exceptional, but the overall talent that's out there and the quality of the product we received on YouTube was amazing."
PREVIOUS AGENCY ‹‹ HOME ›› NEXT AGENCY
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.